Check Your GLP-1 Provider's Public Record
FDA Warning & Transparency Checker
This database currently documents 13 sourced FDA warning-letter records dated September 9, 2025 through June 8, 2026. Enter a provider's name to review the records we found. This is a public-record check, not a determination that care or medication is safe.
Database includes 25 reviewed entries without a sourced warning and 13 entries with sourced FDA warnings
Red Flags to Watch For
Guaranteed weight loss claims
Legitimate providers never guarantee specific results. Claims like "lose 30 lbs in 30 days" are a regulatory violation and a sign of deceptive marketing.
No medical evaluation required
Any provider that ships GLP-1 medication without a proper medical evaluation (health history, BMI assessment, contraindication screening) is cutting dangerous corners.
Won't name their pharmacy partner
Legitimate providers transparently disclose which compounding pharmacy prepares their medications. Refusal to share this information is a major red flag.
Claims compounded drugs are "identical" to brand-name
Compounded semaglutide is NOT the same as Wegovy or Ozempic. Any provider claiming equivalence is misleading you and violating FDA regulations.
Prices that seem too good to be true
Compounded semaglutide has real costs (pharmacy, ingredients, clinical oversight). Prices under $100/month for an all-inclusive program warrant scrutiny.
No ongoing medical supervision
Auto-refill programs with no check-ins or dose adjustments are dangerous. GLP-1 medications require titration and monitoring, especially during the first few months.
Aggressive social media advertising
Many FDA-warned companies relied heavily on Instagram and TikTok ads with before/after photos and influencer endorsements. Legitimate providers focus on clinical outcomes.
How We Review Provider Records
Our public-record and transparency review examines five dimensions for every GLP-1 provider in this database. It is not a clinical safety certification:
FDA Enforcement History
We record a warning only when the row links to the official FDA letter and includes the date we checked it. No row in this finite tracker is not proof of no enforcement history.
Pharmacy Licensing Verification
We display a licensing status or 503A/503B classification only when that exact claim has a source and verification date. Otherwise the field is Unknown.
NABP Accreditation Check
We display NABP accreditation only when a claim-level source and check date support it. An unverified field remains Unknown, not No or Yes.
Operational Track Record
We record operating tenure and BBB status only when sourced and dated. Neither is a clinical-safety or regulatory-compliance score.
Transparency Assessment
We evaluate whether providers disclose their pharmacy partners, medical team credentials, pricing structure, and compounding practices.
FDA Warning Letters Explained
An FDA warning letter is a formal communication from the U.S. Food and Drug Administration describing apparent violations and requesting corrective action. In the context of compounded GLP-1 medications, a letter may concern issues such as:
- Misleading marketing claims, suggesting compounded semaglutide is identical to, or as effective as, FDA-approved brands like Wegovy or Ozempic
- Unapproved new drug claims, marketing compounded medications for indications they haven't been approved for
- Improper compounding practices, operating without proper pharmacy licenses, inadequate sterility controls, or using unlicensed facilities
- No valid patient-provider relationship, dispensing prescription medications without a proper medical evaluation
Warning letters are public records. The response deadline and cited violations appear in each letter, and the FDA may pursue further enforcement if concerns are not corrected. A warning letter is not, by itself, proof that a specific dispensed medication was unsafe.
Frequently Asked Questions
What does an FDA warning letter mean for a GLP-1 provider?
An FDA warning letter describes apparent violations the agency identified and asks the company to correct them. It is a serious public regulatory record, but it does not by itself prove that a particular dispensed medication was unsafe. Read the exact letter, check whether the FDA has published a close-out letter, and ask the provider and your prescriber what changed.
Are compounded GLP-1 medications safe?
The FDA does not approve compounded drugs or review them for safety, effectiveness, or quality before marketing. A state-licensed 503A pharmacy or FDA-registered 503B outsourcing facility is not a safety guarantee. Ask your prescriber whether a compounded product is medically appropriate, identify the dispensing pharmacy, and verify its current license or registration.
What's the difference between a 503A and 503B compounding pharmacy?
Section 503A pharmacies generally compound for identified patients under state pharmacy oversight. Section 503B outsourcing facilities register with the FDA, may compound certain drugs in bulk, and are subject to federal current good manufacturing practice requirements and FDA inspection. Neither status means the FDA approved a compounded product.
How can I investigate a GLP-1 provider?
Identify the prescribing clinician and dispensing pharmacy, verify their current licenses with the relevant state boards, review FDA warning and close-out letters, and check whether pricing, follow-up care, and cancellation terms are disclosed. Be wary of guaranteed weight-loss claims. No single database entry or badge establishes medication safety.
Which FDA warning letters does this checker currently cover?
This checker currently documents 13 sourced FDA warning-letter records dated September 9, 2025 through June 8, 2026. That is the coverage of this database, not a claim to include every FDA action. Each warning result identifies the cited issue and links to the official letter; the allegations vary by company.
Should I stop taking my GLP-1 medication if my provider received a warning?
Do not stop or change a prescribed medication solely because a warning appears here. Read the official letter, ask the provider how it responded and which pharmacy dispensed your medication, and discuss the record with your prescriber or pharmacist. Seek urgent medical care for severe or emergency symptoms.
Compare Providers With Checked Records
Our rankings combine provider data with the public-record checks documented here. Rankings are not medical or safety certifications.
View Provider Rankings →Keep Researching Before You Start
Safety is about more than the provider. Read up on the medication itself next:
- GLP-1 Safety Center → Our full hub on risks and red flags.
- GLP-1 Side Effects → What to expect and when to call a doctor.
- FDA Alerts → Latest warning letters and recalls.
- Lawsuit Tracker → Active GLP-1 litigation, updated.
This tool is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or switching GLP-1 medications. Public-record data is compiled from public FDA records, state pharmacy board databases, and our independent research. Last reviewed August 14, 2026.